In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Verve Therapeutics (VERV – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $6.08.
According to TipRanks, Issi is an analyst with an average return of -23.6% and a 20.00% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Verve Therapeutics is a Strong Buy with an average price target of $27.86, implying a 358.22% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
VERV market cap is currently $477.6M and has a P/E ratio of -1.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verve Therapeutics (VERV) Company Description:
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
Read More on VERV:
- Verve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
- Verve Therapeutics announces dosing of first patient in VERVE-102 trial
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics initiated with a Buy at H.C. Wainwright
- Verve Therapeutics price target lowered to $40 from $56 at Stifel
